Error loading player: No playable sources found

64143

Parallel Session 4: Considerations for CGTP Delivery Device Development

Date
June 27, 2023
This product is not available for individual purchase, but it is available as part of the following products:
Thumbnail for CGTP Summit 2023 / Cell and Gene Therapy Products Symposium 2023
The Cell and Gene Therapy Products (CGTP) Symposium: Manufacturing, Quality and Regulatory Considerations enables the exchange of scientific ideas and dialogue with regulators that form the basis of evolving regulatory practices in the development of these diverse and innovative products…

Many cell and gene therapy products use special delivery devices. Generally, there are two approaches for development and commercialization. 1: specify a device brand in the label to be used with the cell or gene therapy products. Under this approach, the sponsor is developing a drug/device combination product, need to navigate complex, often rather different, regulatory pathways in different countries, regions. 2: not to specify a brand but only describe device characteristics so that end users can source the device on their own to the defined characteristics. Under this approach, the sponsor needs to consider data required to support drug compatibility with potentially a class of device products. The US FDA has issued a guidance in 2019 on CGTP delivery devices. In the EU, regulatory requirements differ between integral, non-integral co-packaged, or not co-packaged (e.g. referenced) medical devices. In addition, distinct legislative frameworks for medicinal products and medical devices require joint input of respective experts. 




This session will use case studies to explore and discuss each approach, share lessons learned during early and late stage CGTP development on managing regulatory procedures, overcoming regulatory hurdles.




Session Speakers:




The Regulatory Interface of ATMPs and Medical Devices in Europe 

Ilona Reischl, Austrian Medicines and Medical Devices Agency




U.S. FDA’s Perspective on Delivery Devices Used to Administer Cell and Gene Therapy Products 

Laura Ricles, CBER, FDA




What Device Engineers Can Teach You About CGTP Delivery Devices 

Saran Baskaran, AstraZeneca
Samir Shah, AstraZeneca

Related Products

Thumbnail for Parallel Session 6: Allogeneic Cell-based Therapies: Next Frontier in Advanced Therapies
Parallel Session 6: Allogeneic Cell-based Therapies: Next Frontier in Advanced Therapies
Allogeneic cell therapies have a potential to revolutionize life-saving Cell and Gene therapy (CGT) field by removing the bottlenecks created by long scheduling delays, lengthy manufacturing times and potential product failures of autologous cell therapies…
Thumbnail for Plenary Session 5: Challenges with Incoming Materials - Raw, Starting, Ancillary, etc.
Plenary Session 5: Challenges with Incoming Materials - Raw, Starting, Ancillary, etc.
Raw material selection decisions early in the development of ATMPs are crucial and can impact the final product quality and ultimately patient safety…
Thumbnail for Parallel Session 1: CMC Challenges with Ultra Rare Diseases
Parallel Session 1: CMC Challenges with Ultra Rare Diseases
Bringing treatment to those afflicted with an ultra-rare disease is complex. These products are encumbered with challenges ranging from high development costs with a limited ROI, to issues with executing and interpreting clinical trials with unusually small patient populations…
Thumbnail for Parallel Session 7: Unique Challenges of Stability Testing for Cell and Gene Therapy Products
Parallel Session 7: Unique Challenges of Stability Testing for Cell and Gene Therapy Products
Cell and Gene Therapy programs are progressing from early academic settings to commercial manufacturing at increasingly faster pace and in greater numbers. These therapies are complex, difficult to manufacture in large quantities, and involve many bespoke technologies to make, test and release…